SL-401 and SL-501, Targeted Therapeutics Directed at the Interleukin-3 Receptor, Inhibit the Growth of Leukaemic Cells and Stem Cells in Advanced Phase Chronic Myeloid Leukaemia

While imatinib and other tyrosine kinase inhibitors (TKIs) are highly efficacious in the treatment of chronic myeloid leukaemia (CML), some patients become refractory to these therapies. After confirming that interleukin-3 receptor (IL3R, CD123) is highly expressed on CD34(+)/CD38(−) BCR-ABL1(+) CML...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Frolova, Olga, Benito, Juliana, Brooks, Chris, Wang, Rui-Yu, Korchin, Borys, Rowinsky, Eric K., Cortes, Jorge, Kantarjian, Hagop, Andreeff, Michael, Frankel, Arthur E., Konopleva, Marina
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4146738/
https://ncbi.nlm.nih.gov/pubmed/24942980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12978
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados